Seikagaku up 5.9% in 2Q19 on US Reimbursement

Seikagaku grew in the mid-single digits on increased volumes of their Gel-One viscosupplement and favorable reimbursement decisions from U.S. insurers.

• Domestic shipments of ARTZ decreased in volume, but were partially offset by delayed orders from previous quarters
• International sales of the Gel-One viscosupplement increased due to marketing efforts and favorable reimbursement decisions from insurers
• Sales of five-injection SUPARTZ FX declined as the U.S. market shifts toward single-injection treatments

Performance by Segment

ORTHOWORLD estimates segment sales and growth on an as-reported basis, as follows ($MM):

Source: Seikagaku

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.